Brokerages Set IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Price Target at $29.13


Share on StockTwits

Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) have been given an average recommendation of “Buy” by the nine analysts that are presently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a hold rating and six have given a buy rating to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $29.13.

A number of research analysts have weighed in on IDYA shares. Citigroup increased their target price on IDEAYA Biosciences from $20.00 to $33.00 in a report on Wednesday, March 24th. Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell increased their target price on IDEAYA Biosciences from $20.00 to $33.00 in a report on Wednesday, March 24th. Wedbush increased their target price on IDEAYA Biosciences from $25.00 to $32.00 and gave the company an “outperform” rating in a report on Monday, March 15th. Finally, Guggenheim started coverage on IDEAYA Biosciences in a report on Wednesday, March 17th. They issued a “buy” rating and a $32.00 target price on the stock.

IDEAYA Biosciences stock opened at $20.89 on Monday. IDEAYA Biosciences has a one year low of $4.01 and a one year high of $24.92. The stock has a market capitalization of $673.91 million, a PE ratio of -11.11 and a beta of 2.11. The business’s fifty day moving average is $21.34 and its 200 day moving average is $16.24.

IDEAYA Biosciences (NASDAQ:IDYA) last posted its earnings results on Monday, March 22nd. The company reported ($0.18) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.12. The firm had revenue of $10.57 million during the quarter, compared to the consensus estimate of $10.88 million. As a group, research analysts anticipate that IDEAYA Biosciences will post -1.48 earnings per share for the current fiscal year.

In related news, SVP Michael P. Dillon sold 5,000 shares of the stock in a transaction dated Tuesday, February 9th. The stock was sold at an average price of $20.74, for a total transaction of $103,700.00. Following the completion of the sale, the senior vice president now owns 103,789 shares in the company, valued at $2,152,583.86. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Mark Lackner sold 2,501 shares of the stock in a transaction dated Tuesday, January 26th. The stock was sold at an average price of $18.46, for a total value of $46,168.46. The disclosure for this sale can be found here. 20.70% of the stock is owned by company insiders.

Several large investors have recently added to or reduced their stakes in IDYA. Citigroup Inc. grew its position in shares of IDEAYA Biosciences by 407.6% during the fourth quarter. Citigroup Inc. now owns 3,883 shares of the company’s stock worth $54,000 after purchasing an additional 3,118 shares in the last quarter. DekaBank Deutsche Girozentrale purchased a new position in IDEAYA Biosciences during the 4th quarter valued at approximately $124,000. The Manufacturers Life Insurance Company purchased a new position in IDEAYA Biosciences during the 4th quarter valued at approximately $149,000. Bourgeon Capital Management LLC grew its holdings in IDEAYA Biosciences by 2,723.3% during the 4th quarter. Bourgeon Capital Management LLC now owns 11,293 shares of the company’s stock valued at $158,000 after buying an additional 10,893 shares in the last quarter. Finally, State of Michigan Retirement System purchased a new position in IDEAYA Biosciences during the 4th quarter valued at approximately $161,000. Hedge funds and other institutional investors own 62.27% of the company’s stock.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, an oncology-focused precision medicine company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's product candidate is IDE196, a protein kinase C inhibitor that is in Phase 1/2 clinical trial for genetically-defined cancers having GNAQ or GNA11 gene mutations.

Recommended Story: Different Types of Derivatives

Analyst Recommendations for IDEAYA Biosciences (NASDAQ:IDYA)

Receive News & Ratings for IDEAYA Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEAYA Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.